Abstract: The present invention relates to 6,7-dihydro-5H-pyrazolo[1,2?]pyrazol-1-ones which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 6,7-dihydro-5H-pyrazolo[1,2?]pyrazol-1-ones and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.
Type:
Grant
Filed:
November 5, 2004
Date of Patent:
January 27, 2009
Assignee:
The Procter & Gamble Company
Inventors:
Michael Philip Clark, Steven Karl Laughlin, Adam Golebiowski, Todd Andrew Brugel, Mark Sabat
Abstract: The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.
Type:
Grant
Filed:
April 21, 2005
Date of Patent:
November 11, 2008
Assignee:
The Procter & Gamble Company
Inventors:
Todd Andrew Brugel, Jennifer Anne Townes, Michael Philip Clark, Mark Sabat, Adam Golebiowski, Biswanath De, Stephen Matthew Berberich, Gregory Kent Bosch
Abstract: A method for providing nutrition to critical care animals such as dogs and cats is provided which comprises administering an amount of an artificially produced canine or feline milk substitute composition. The canine milk substitute composition comprises, on a dry matter basis, from about 35 to 45% by weight protein, from about 25 to 35% by weight fat, and from about 10 to 25% by weight carbohydrates. The feline milk composition comprises, on a dry matter basis, from about 30 to 50% protein, from about 25 to 50% fat, and from about 10 to 25% carbohydrates.
Abstract: The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.
Type:
Grant
Filed:
April 21, 2005
Date of Patent:
July 22, 2008
Assignee:
The Procter & Gamble Company
Inventors:
Todd Andrew Brugel, Jennifer Anne Townes, Michael Philip Clark, Mark Sabat, Adam Golebiowski, Biswanath De
Abstract: The present invention relates to 2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, having the formula: and pharmaceutical compositions thereof, and methods for controlling the level of one or more inflammation inducing cytokines selected from the group consisting of, interleukin-1 (IL-1), Tumor Necrosis Factor-? (TNF-?), interleukin-6 (IL-6), and interleukin-8 (IL-8), thereby controlling, mediating, or abating disease states affected by the level of extracellular inflammatory cytokines in humans.
Type:
Grant
Filed:
June 23, 2005
Date of Patent:
May 6, 2008
Assignee:
The Procter & Gamble Company
Inventors:
Michael Philip Clark, Matthew John Laufersweiler
Abstract: The present invention relates to methods for treating diseases or disease states which are mediated or otherwise affected by the extracellular release of cytokines, said method comprising the step of administering to a human or higher mammal in need of treatment, one or more of the 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones of the present invention.
Type:
Grant
Filed:
August 19, 2004
Date of Patent:
February 5, 2008
Assignee:
The Procter & Gamble Company
Inventors:
Michael Philip Clark, Robert Arthur Lyon
Abstract: The present invention relates to a method for determining whether a compound is capable of binding to a BMP receptor kinase protein complex, the method comprising introducing a sample comprising the compound to the BMP receptor kinase protein complex and allowing the compound to bind to the BMP receptor kinase protein complex, wherein the BMP receptor kinase protein complex is comprised of a BMP type I receptor kinase protein and the BMP receptor kinase protein BRK-3. The invention further relates to a method for determining the concentration of a BMP receptor ligand in a clinical sample, the met-hod comprising introducing the sample comprising the ligand to a BMP receptor kinase protein complex and allowing the ligand to bind to the BMP receptor kinase protein complex, wherein the BMP receptor kinase protein complex is comprised of a BMP type I receptor kinase protein and BMP receptor kinase protein BRK-3.
Abstract: The present invention is for compositions and methods for managing the body weight of a subject using said compositions. Weight management, particularly weight gain and loss, is effectuated by producing a sensation of satiety in said subjects. The method of managing body weight includes administering the composition prior to food consumption, concurrent with food consumption, as replacement for food consumption and combinations thereof.
Type:
Grant
Filed:
June 26, 2000
Date of Patent:
April 11, 2006
Assignee:
The Procter & Gamble Company
Inventors:
Ronald James Jandacek, Gary Robert Kelm, Satinder Singh Bharaj, Jorge Villanueva Penafiel